TCTR20260718006进行中（未招募）4 期
A Prospective Study of the Efficacy and Safety of Polycaprolactone (PCL) Collagen Stimulator in Facial Rejuvenation and Contouring
Rungsima Wanitphakdeedecha0 个研究点目标入组 30 人开始时间: 2026年7月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30 Years 至 60 Years（—）
- 性别
- All
入选标准
- •moderate-severe photoaging
- •mild-moderate facial laxity
排除标准
- •Pregnant or breastfeeding women
- •patients with history of platelet disorders, coagulation abnormalities, anemia, liver disease, cancer, or autoimmune disorders.
- •Patients who smoke or have a history of excessive alcohol consumption (defined as a smoking history of more than 20 pack-years and alcohol consumption exceeding 15 standard drinks per week for men or 8 standard drinks per week for women).
- •Patients with facial dermatitis, wounds, or skin infections at the treatment site.
- •Patients with a history of allergy to local anesthetic agents.
- •Patients who currently taking medications that affect blood coagulation, such as aspirin or anticoagulants.
- •Individuals who have undergone laser treatment, radiofrequency treatment, thread lifting, or other facial tightening procedures within 6 months prior to study enrollment.
- •Individuals who have undergone facial chemical peeling within 6 months prior to study enrollment.
- •Individuals who have received botulinum toxin injections to the face within 6 months prior to study enrollment.
- •Patients who have received dermal filler injections or platelet-rich plasma (PRP) injections to the face within 6 months prior to study enrollment.
- •Patients with a history of hypertrophic scar or keloid formation.
- •Patients with psychiatric disorders previously diagnosed by a psychiatrist.
研究组 & 干预措施
Patients will be treated with 2.4 mL of PCL filler administered at 10 predetermined injection points on the face. Follow-up visits will be scheduled at 1, 3, 6, 9, and 12 months after treatment.;Experimental Drug;PCL filler
干预措施: Patients will be treated with 2.4 mL of PCL filler administered at 10 predetermined injection points on the face. Follow-up visits will be scheduled at 1, 3, 6, 9, and 12 months after treatment.;Experimental Drug;PCL filler
研究者
相似试验
招募中
不适用
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease (J2A-MC-GZPR)Peripheral Arterial DiseasejRCT20312505701,205
招募中
不适用
An Exploratory Study of novel diuretic therapy for cirrhotic ascitesLiver cirrhosis with uncontrolled ascites complicated by Type 2 diabetes mellitusjRCT103125078610
招募中
1 期
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants with Advanced Solid MalignanciesParticipants with Advanced Solid Malignancies2024-511453-22-00Kumquat Biosciences Inc.112
招募中
2 期
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progressionGlioblastoma2022-501822-39-00Philogen S.p.A.113
进行中（未招募）
Unknown
Effectiveness of OjasNoor Renewal Serum for BrighteningCTRI/2026/07/114186VedaLume Private Limited, OjasNoor36